Human Neural Stem Cell Extracellular Vesicles Improve Tissue and Functional Recovery in the Murine Thromboembolic Stroke Model
- 7.3k Downloads
Over 700 drugs have failed in stroke clinical trials, an unprecedented rate thought to be attributed in part to limited and isolated testing often solely in “young” rodent models and focusing on a single secondary injury mechanism. Here, extracellular vesicles (EVs), nanometer-sized cell signaling particles, were tested in a mouse thromboembolic (TE) stroke model. Neural stem cell (NSC) and mesenchymal stem cell (MSC) EVs derived from the same pluripotent stem cell (PSC) line were evaluated for changes in infarct volume as well as sensorimotor function. NSC EVs improved cellular, tissue, and functional outcomes in middle-aged rodents, whereas MSC EVs were less effective. Acute differences in lesion volume following NSC EV treatment were corroborated by MRI in 18-month-old aged rodents. NSC EV treatment has a positive effect on motor function in the aged rodent as indicated by beam walk, instances of foot faults, and strength evaluated by hanging wire test. Increased time with a novel object also indicated that NSC EVs improved episodic memory formation in the rodent. The therapeutic effect of NSC EVs appears to be mediated by altering the systemic immune response. These data strongly support further preclinical development of a NSC EV-based stroke therapy and warrant their testing in combination with FDA-approved stroke therapies.
KeywordsNeural stem cell extracellular vesicles Thromboembolic stroke Preclinical stroke model
Despite the overwhelming global need, intravenous tissue plasminogen activator (IV-tPA) and endovascular thrombectomy (ET) are the only two FDA-approved stroke therapies to date [1, 2]. Both of the above “reperfusion” therapies target opening of major blood vessels in a carefully diagnosed, yet a very small sub-population of stroke victims. While reperfusion could itself trigger a secondary injury, neither of the FDA-approved stroke therapies are directly neuroprotective or neuroregenerative. Moreover, the use of IV-tPA and/or ET is improbable as a field therapy and both are limited to state-of-the-art facilities [3, 4]. Therefore, a larger population of stroke patients with limited access to these facilities (e.g., rural populations) still remain untreated and often rely on later neurorehabilitation and endogenous neuroregeneration mechanisms [5, 6].
Ideally, an implementable therapy would protect the brain in acute stroke and enhance long-term functional outcomes among stroke survivors. Along these lines, the Stroke Treatment Academic Industry Roundtable (STAIR) recommends development of stroke therapies, which could reduce reperfusion injury and promote neurovascular plasticity and recovery later. An assessment of the litany of failed treatments by the Stem Cell Emerging Paradigm in Stroke Consortium meetings (STEPS I, II, and III) resulted in identifying major treatment deficiencies including (1) lack of a regenerative therapy that will not only protect cells from ischemic injury but stimulate regeneration of lost and damaged tissues and (2) translational animal models more reflective of human pathology and improved predictive testing of treatments [7, 8].
One of the most promising therapeutic avenues capable of addressing this need for a neuroprotective and/or regenerative therapy is the use of extracellular vesicles (EVs) . EVs are membrane shed microvesicles (50–1000 nm) and exosomes (40–150 nm) produced by all cells of the central nervous system (CNS) [10, 11]. The therapeutic development of EVs is being explored for multiple regenerative therapeutic scenarios, as EVs overcome many of the limitations of cell therapies, including but not limited to the ability to deliver multiple doses, as well as the ability to store and administer EVs without specialized equipment or advanced training for medical personnel .
While reports on EV therapeutic benefits in rodent studies of mechanically occluded stroke (both transient suture and permanent electrocauterization models) are encouraging, optimal therapeutic EV sources have not been explored [13, 14]. Previously published stroke studies utilized non-neural sourced mesenchymal stem cell (MSC) EVs administered systemically into rodent models and produced behavioral improvements without significant reductions in infarct volume [13, 14, 15]. However, there are many indications that EV cargoes are cell type specific and the parental cell line plays a prodigious role in the biological properties of the resultant EV . Therefore, EVs derived from different sources (MSC vs. NSC cells) may have unique properties relative to cell type. Also, the context under which EVs are produced directly influences the signal that the resultant EVs communicate [16, 17]. For example, EVs extracted from sera of stroke patients induced inflammatory cytokine expression in vitro . Together, cell-specific activity and systemic immunological activation are novel multifaceted means by which EVs may provide beneficial effects in both local and systemic processes post-ischemic insult . While specific mechanism(s) of action are still being investigated, the potential therapeutic mechanisms of EVs appear to include anti-oxidative, pro-angiogenic, immunomodulatory, and/or neural plasticity regulating processes [20, 21]. Additionally, since the majority of stroke (~ 87%) occurs due to a thromboembolic (TE) occlusion and a larger population of victims remains untreated with the FDA-approved reperfusion therapies, it is critical to validate this promising therapy in a physiologically relevant TE model of stroke [9, 22, 23].
The objective of this study was to evaluate the therapeutic potential of human neural stem cell-derived EVs in a highly relevant preclinical stroke model without immunosuppression. NSC EV treatment significantly decreased neural injury in the murine model of TE stroke and also resulted in decreased behavioral and motor function deficits.
Pluripotent Stem Cell-Derived NSC and MSC EVs Were Similar in Structural and Protein Marker Expression But Not in Size
NSC EVs Provided Significant Benefits in the Murine Embolic Model
NSC EV Treatment Reduced Lesion Volume and Improved Behavioral Outcomes in Aged Mice
Stroke therapeutics are often tested in young animals within a narrow time range post-stroke. NSC EVs were further explored in aged mice (18 ± 1 months), starting approximately 6 h post-stroke, to fall outside the time window of traditional tPA administration in humans. Dosage in the embolic model was maintained constant; however, the administration window was shifted to 6, 24, and 48 h post-stroke. (Fig. 4a). Blinded investigators randomly divided mice into non-stroked (sham) and stroked with either PBS vehicle (control) or NSC EV in PBS treatment groups (N = 24 animals/group). Analysis of T2-weighted (T2W) sequences 2 days post-TE-MCAO indicated a significant decrease in lesion volume in NSC EV-treated animals (58.2 ± 5.03 and 37.9 ± 2.84 mm3, respectively) (Fig. 4b, c), while ex vivo Q-ball MRI (performed on the fixed brain post-euthanasia) indicated that NSC EV treatment attenuated the post-stroke cerebral atrophy and significantly decreased it compared to the vehicle-treated group (22.8 ± 0.40 and 10.6 ± 1.94% of contralateral hemisphere) (Fig. 4d). Diffusion tensor imaging (DTI) and fractional anisotropy (FA) analysis was also performed after Q-ball imaging; however, no significant differences in diffusivity or white matter integrity were observed between the two groups subjected to TE stroke, which is likely due to less white matter content in small rodents.
We present here the first experimental evidence that NSC EVs improve cellular, tissue, and functional outcomes in the murine TE-MCAO models. Mitigating the secondary injury cascades, particularly the immune response, NSC EV intervention led to significantly decreases in infarct size and brain atrophy, which has never been observed acutely in previous studies of exosome treatment for stroke [13, 14, 15]. Although various cell therapies have improved stroke recovery in preclinical models, NSC EVs possess a number of advantages over cell-based therapeutics including decreased tumorigenicity, limited immunogenicity, enhanced biodistribution, and BBB permeability [13, 29, 30, 31]. In addition, vesicles are involved in many biological processes with the potential to serve as a neuroprotective and translatable therapeutic for neural disabilities including ischemic stroke and, importantly, can likely be used in conjunction with currently available tPA and/or endovascular therapies [32, 33]. Tissue level changes generated large-scale reductions in neural injury and rapid recovery of neurological and motor function outcomes in vivo, thus suggesting NSC EVs are a promising therapeutic for human patients.
Functional benefits following MSC EV treatment for stroke has been evaluated using several different cell lines, with varying degrees of MSC marker definition and EV dose [13, 14, 34]. However, benefits in the infarct, including evidence of axonal remodeling and angiogenesis in the ischemic boundary zone were achieved using EVs from cells modified by a lentivirus, indicating that modification can influence therapeutic potential of the resultant EVs . Uniquely, the MSC EVs tested were of PSC origin and differentiated in vivo. We have shown previously that although these cells have many of the common markers (CD73, CD93, and CD105), they can have unique differentiation potential and methylation patterns . MSC sourced using different tissue origins, isolation methods, and in vitro culture conditions can alter the immunosuppression potency of MSC . Thus, the results here may not represent results obtained by all sources of MSCs. However, these findings do elude to unknown subtleties of screening complex biologics, like EVs, for therapeutic potential in humans.
Stroke is unpredictable and the degree of neuroprotection provided by EVs may likely vary by the efficiency of their delivery into the ischemic brain. Therefore, we tested NSC EVs in two different treatment regimens in murine TE stroke. NSC EVs therapy, as early as 2 h after TE stroke in middle-aged (12 months old) mice, not only improved the neurological outcomes and profoundly reduced the infarction volume but also downregulated the systemic inflammatory response in the blood. It is well established that following stroke, immune cells such as leukocytes infiltrate the brain as a result of increased adhesion phenomena and resultant BBB permeability, leading to a brain localized neuroimmune response . Circulating macrophages can also trigger a long-term adaptive immune response causing chronic neurodegeneration and subsequent neuropsychiatric dysfunction even after closure of the BBB . Naïve immune cells such as macrophages and T lymphocytes are highly plastic in nature, which can adapt to a context-specific functional phenotype depending upon the microenvironment. Activated macrophages can also traverse into the draining cerebro-meningeal lymphatic system to trigger an adaptive immune response, which can decide the fate of outgoing T lymphocytes targeting the injured brain . Since EVs carry a number of proteins, various RNA species, and bioactive lipids capable of diverse signaling, we looked into the systemic immune response 96 h after stroke. Mice treated with repeated doses of NSC EV showed increased M2-type macrophages and Treg populations, with a concurrent decrease in Th17 lymphocytes. Since macrophage activation precedes T lymphocyte proliferation and activation, it is likely that acute treatment with NSC EVs promoted a conducive microenvironment resulting in alternatively (but not classically) activated M2-type polarization. This likely skews T lymphocytes to their regulatory phenotype, (Treg) with concurrent suppression of pro-inflammatory Th17 (an effector phenotype which releases IL-17 and causes long-term neurodegeneration after stroke) . Although these mechanistically novel findings in response to NSC EV therapy need further investigation, it is probable that such responses could have translational importance (Fig. 2); as such, circulating immune cells from the blood could possibly be used as a convenient biomarker to follow chronic effects of disease progression and the therapeutic effect of NSC EV in stroke during long-term follow-up.
Chronic neuropsychiatric dysfunctions such as the exacerbation of depression, anxiety, and dementia in aged individuals are very common after stroke . Therefore, we next evaluated the delayed NSC EV therapy in the reproductively senescent aged (18 months old) mice subjected to TE stroke model and followed them for both acute and chronic outcomes. NSC EV therapy, even in an extended treatment window, reduced the acute lesion volume and cerebral atrophy at 28 days post-stroke. NSC EV-treated stroke mice performed better in various behavioral tasks related to motor function, muscular strength, depression, and learning/memory. Taken together, our data in murine TE stroke strongly supports further development of NSC EV-based stroke therapy.
MRI assessments of infarct volume, atrophy, and brain swelling are pivotal predictors of clinical severity and prognosis and are critical readouts in assessing the efficacy of stroke therapies [42, 43]. NSC EVs administered both within and outside the tPA therapeutic window resulted in a significant decrease in infarct volume in our murine model. In addition, MRI results suggest NSC EVs also resulted in a significant reduction in tissue loss 28 days post-TE-MCAO in aged mice. These findings directly support recent reports in which MSC EVs were found to promote tissue preservation and neurovascular remodeling through proposed paracrine effectors [15, 44, 45].
NSC EVs may promote increases in vascular density and angiogenic processes by mediating specific gene regulation. For example, emerging data suggests downregulation of miR-15a in cerebral vessels in a murine model of ischemic stroke promotes angiogenesis in the peri-infarct region by increasing FGF-2 and VEGF levels [46, 47]. Many MSC EV-related studies have observed improvements in functional recovery, neurogenesis, and angiogenesis in rodent models of ischemic stroke [14, 15, 48, 49]. However, these studies have yet to report a significant difference in acute infarct volume as we have shown here. These results suggest that NSC EVs maybe therapeutically more potent than their MSC EV counterparts. While the exact molecular mechanism(s) responsible for these effects are currently unknown, it is possible that they are mediated by tetraspanin superfamily proteins. We routinely detect tetraspanins CD63 and CD81 in NSC EVs. Tetraspanins affect cell adhesion, motility, proliferation, and coagulation , which we believe may improve stroke outcomes.
It is imperative for the success of translational research to also incorporate behavioral tests that are sensitive to both the area of brain damage and the interventions that are being applied . Neurological deficit scores and adhesive tape removal times revealed significant improvements in NSC EV-treated mice 2 and 4 days post-TE-MCAO, respectively. Furthermore, NSC EVs promoted significant improvements in balance beam walking, the number of footfalls, hanging wire, and tail suspension performance 14 days post-TE-MCAO in aged rodents. In comparison, similar studies evaluating rodent MSC EVs also reported significant behavioral improvements in comparatively young animals, in the absence of changes in infarct volume [14, 34, 52]. However, how rodent MSC EVs evaluated in young adult animals translate to the therapeutic potential of human MSC EVs and how those compare to NSC EVs are frequently not addressed—leaving plausible gaps in our knowledge of how these resources inform further development in preclinical programs for evaluation of EVs for therapeutic use in humans.
In addition to sensorimotor tests, we also evaluated NSC EV effects on declarative memory. Fourteen days post-TE-MCAO, our NSC EVs induced a significant improvement not only in NOR but also in associated NO discrimination performance. This suggests NSC EVs may also support the conservation of key brain regions associated with declarative memory and discrimination, like the dorsolateral prefrontal cortex and the medial temporal lobe [53, 54]. Advanced imaging and pharmacological inactivation studies in multiple animal models have also confirmed this theory by providing evidence that the prefrontal cortex plays a critical role during remote memory recall by regulating the hippocampus . Stroke-induced injury to white matter tracts (including connections to the frontal and temporal cortices) has been linked to lasting deficits in episodic and declarative memory in both rodent models, as well as human patients [55, 56, 57, 58].
This study uniquely encompassed a direct comparison of human MSC and NSC EVs while abiding by STEP and STAIR committee recommendations for developing stroke therapeutics. The extensive testing of NSC EVs has shown impressive biological relevance in the TE-MCAO model of ischemic stroke. By not only decreasing hemispheric swelling, atrophy, and infarct volume but also improving functional performance in vivo, NSC EVs possess potent and translatable therapeutic potential that with further testing may change the current therapeutic paradigm of ischemic stroke. Further testing in large animal models of stroke, as well as studies evaluating the use in conjunction with tPA and endovascular therapies, will further inform the therapeutic development potential of NSC EVs.
The authors would like to thank Caroline Jackson, Justin Sharma, Austin Passaro, and Viviana Martinez who were involved with various aspects of the EV manufacturing process and figure preparation. We would also like to thank Tracey Stice for the project management guidance as well as Beth Richardson and Mary Ard at the University of Georgia Electron Microscopy Core for their technical assistance and expertise.
This work was supported by ArunA Biomedical, Inc., and R.L.S. was partially supported by the Science and Technology Center Emergent Behaviors of Integrated Cellular Systems (EBICS) Grant No. CBET-0939511.
Compliance with Ethical Standards
Conflict of Interest
R.L.W. and S.L.S. have submitted a patent filing on the NSC EVs, and this technology is licensed from the UGA Research Foundation by ArunA Biomedical, Inc. R.L.W., S.L.S., T.A.T., R.L.S., and S.L.S. are affiliated with ArunA Biomedical, Inc. and own equity in the company. E.E.K., S.F., C.P., K.S., K.V., A.S.A., B.B., K.M.D., D.C.H., and M.N.H. declare that they have no conflict of interest.
All animal procedures were approved by the Institutional Animal Care and Use Committee of Augusta University. This article does not contain any studies with human participants performed by any of the authors.
- 3.Adams HP, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al. Guidelines for the early management of adults with ischemic stroke. A guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. 2007;115(20):e478–534. https://doi.org/10.1161/circulationaha.107.181486.
- 4.Duncan PW, Zorowitz R, Bates B, Choi JY, Glasberg JJ, Graham GD, et al. Management of adult stroke rehabilitation care. A Clinical Practice Guideline. Stroke. 2005;36(9):e100–e43. https://doi.org/10.1161/01.str.0000180861.54180.ff.CrossRefPubMedGoogle Scholar
- 7.Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS): bridging basic and clinical science for cellular and neurogenic factor therapy in treating stroke. Stroke. 2009;40(2):510–5. https://doi.org/10.1161/STROKEAHA.108.526863.
- 12.Gimona M, Pachler K, Laner-Plamberger S, Schallmoser K, Rohde E. Manufacturing of human extracellular vesicle-based therapeutics for clinical use. Int J Mol Sci. 2017;18(6) https://doi.org/10.3390/ijms18061190.
- 13.Doeppner TR, Herz J, Görgens A, Schlechter J, Ludwig A-K, Radtke S, et al. Extracellular vesicles improve post-stroke neuroregeneration and prevent postischemic immunosuppression. Stem Cells Transl Med. 2015;4(10):1131–43. https://doi.org/10.5966/sctm.2015-0078.CrossRefPubMedPubMedCentralGoogle Scholar
- 14.Xin H, Li Y, Cui Y, Yang JJ, Zhang ZG, Chopp M. Systemic administration of exosomes released from mesenchymal stromal cells promote functional recovery and neurovascular plasticity after stroke in rats. J Cereb Blood Flow Metab. 2013;33(11):1711–5. https://doi.org/10.1038/jcbfm.2013.152.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Zhang Y, Chopp M, Zhang ZG, Katakowski M, Xin H, Qu C, et al. Systemic administration of cell-free exosomes generated by human bone marrow derived mesenchymal stem cells cultured under 2D and 3D conditions improves functional recovery in rats after traumatic brain injury. Neurochem Int. 2016; https://doi.org/10.1016/j.neuint.2016.08.003.
- 16.Wiklander OPB, Nordin JZ, O’Loughlin A, Gustafsson Y, Corso G, Mäger I et al. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J Extracell Vesicles. 2015;4. https://doi.org/10.3402/jev.v4.26316
- 22.Hoda MN, Fagan SC, Khan MB, Vaibhav K, Chaudhary A, Wang P, et al. A 2 × 2 factorial design for the combination therapy of minocycline and remote ischemic perconditioning: efficacy in a preclinical trial in murine thromboembolic stroke model. Exp Transl Stroke Med. 2014;6(1):10. https://doi.org/10.1186/2040-7378-6-10.CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Yang T, Fogarty B, LaForge B, Aziz S, Pham T, Lai L, et al. Delivery of small interfering RNA to inhibit vascular endothelial growth factor in zebrafish using natural brain endothelia cell-secreted exosome nanovesicles for the treatment of brain cancer. AAPS J. 2017;19(2):475–86. https://doi.org/10.1208/s12248-016-0015-y.CrossRefPubMedGoogle Scholar
- 31.Saari H, Lazaro-Ibanez E, Viitala T, Vuorimaa-Laukkanen E, Siljander P, Yliperttula M. Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of paclitaxel in autologous prostate cancer cells. J Control Release. 2015;220(Pt B):727–37. https://doi.org/10.1016/j.jconrel.2015.09.031.CrossRefPubMedGoogle Scholar
- 34.Xin H, Li Y, Liu Z, Wang X, Shang X, Cui Y, et al. MiR-133b promotes neural plasticity and functional recovery after treatment of stroke with multipotent mesenchymal stromal cells in rats via transfer of exosome-enriched extracellular particles. Stem Cells. 2013;31(12):2737–46. https://doi.org/10.1002/stem.1409. CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Klinker MW, Marklein RA, Lo Surdo JL, Wei CH, Bauer SR. Morphological features of IFN-gamma-stimulated mesenchymal stromal cells predict overall immunosuppressive capacity. Proc Natl Acad Sci U S A. 2017;114(13):E2598–E607. https://doi.org/10.1073/pnas.1617933114. CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Shichita T, Sugiyama Y, Ooboshi H, Sugimori H, Nakagawa R, Takada I, et al. Pivotal role of cerebral interleukin-17-producing [gamma][delta]T cells in the delayed phase of ischemic brain injury. Nat Med. 2009;15(8):946–50. http://www.nature.com/nm/journal/v15/n8/suppinfo/nm.1999_S1.html CrossRefPubMedGoogle Scholar
- 44.Otero-Ortega L, Gomez de Frutos MC, Laso-Garcia F, Rodriguez-Frutos B, Medina-Gutierrez E, Lopez JA, et al. Exosomes promote restoration after an experimental animal model of intracerebral hemorrhage. J Cereb Blood Flow Metab. 2017; https://doi.org/10.1177/0271678X17708917.
- 48.Zhang Y, Chopp M, Meng Y, Katakowski M, Xin H, Mahmood A, et al. Effect of exosomes derived from multipluripotent mesenchymal stromal cells on functional recovery and neurovascular plasticity in rats after traumatic brain injury. J Neurosurg. 2015;122(4):856–67. https://doi.org/10.3171/2014.11.JNS14770.CrossRefPubMedPubMedCentralGoogle Scholar
- 49.Otero-Ortega L, Laso-Garcia F, Gomez-de Frutos MD, Rodriguez-Frutos B, Pascual-Guerra J, Fuentes B, et al. White matter repair after extracellular vesicles administration in an experimental animal model of subcortical stroke. Sci Rep. 2017;7:44433. https://doi.org/10.1038/srep44433.CrossRefPubMedPubMedCentralGoogle Scholar
- 52.Xin H, Wang F, Li Y, QE L, Cheung WL, Zhang Y, et al. Secondary release of exosomes from astrocytes contributes to the increase in neural plasticity and improvement of functional recovery after stroke in rats treated with exosomes harvested from microRNA 133b-overexpressing multipotent mesenchymal stromal cells. Cell Transplant. 2017;26(2):243–57. https://doi.org/10.3727/096368916X693031.CrossRefPubMedPubMedCentralGoogle Scholar
- 53.Blum S, Hebert AE, Dash PK. A role for the prefrontal cortex in recall of recent and remote memories. Neuroreport. 2006;17(3):341–4. https://doi.org/10.1097/01.wnr.0000201509.53750.bc.CrossRefPubMedGoogle Scholar
- 57.Tulving E, Markowitsch HJ. Episodic and declarative memory: role of the hippocampus. Hippocampus. 1998;8(3):198–204. https://doi.org/10.1002/(SICI)1098-1063(1998)8:3<198::AID-HIPO2>3.0.CO;2-G.CrossRefPubMedGoogle Scholar
- 58.Lundy-Ekman L. Neuroscience : fundamentals for rehabilitation. 4th ed. St. Louis: Elsevier; 2013.Google Scholar
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.